“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."
“Initially, ovarian cancer, melanoma, and some sarcomas are the three main targets,” says Dr. Koya, “but the clinical trial is open for patients with other cancers who meet the eligibility requirements."
Collected last week from a patient with late-stage ovarian cancer, these are not ordinary T cells; they have been altered and multiplied in the hope that when they are given back to her, they will launch a devastating attack on her cancer cells.